Robert Cyran
Robert Cyran moved from the London office to New York, where he covers global technology, pharmaceuticals and special situations. Rob began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
Contact Info
- Tel: +1 646 223 6083
- E-mail: robert.cyran@thomsonreuters.com
Recent stories
-
Security is diversion in $20 bln-plus Sprint fight
SoftBank and Dish Network have pulled out the stops in their battle to control the U.S. cellphone operator. But SoftBank has the edge. The claim that Japanese ownership of Sprint is a risk to national security is half-baked and shows Dish boss Charlie Ergen’s desperation.
-
Property investors take pitiful governance cake
Shareholders ousted directors at two U.S. real estate investment trusts managed by the same family company, only to have the boards reappoint them. It’s just the latest example of the wretched practices plaguing a sector that deserves the same activist treatment as the oil patch.
-
Even losers win from $5 bln Actavis deal
Investors loved it when the generic drug firm was the subject of buyout talks. Now they’re just as pleased that Actavis is buying smaller Warner Chilcott instead. The sector is so ripe for consolidation that it’s hard to come up with any combination that investors won’t embrace.
- Cisco stock luxuriates in low expectations
- Bigger really is better in generic drug mergers
- Speech-tech firm's M&A machine could go in reverse
- Oil patch excesses tar all players with same brush
- Wall Street plays pass the biotech parcel
- Dish's pay-TV pain signals trouble for Sprint bid
- BMC deal shows how activist playbook brings profit
